Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

Coiffier, Bertrand; Pro, Barbara; Miles Prince, H.; M. Foss, Francine; Sokol, Lubomir; Greenwood, Matthew; Caballero, Dolores; Borchmann, Peter; Morschhauser, Franck; Wilhelm, Martin; Pinter‐Brown, Lauren; Padmanabhan, Swaminathan; R. Shustov, Andrei; Nichols, Jean; Carroll, Susan; Balser, John; Balser, Barbara; McCue Horwitz, Sarah

doi:10.1200/jco.2011.37.4223

Public

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

Published in Journal of Clinical Oncology • Jan 24, 2012

Authors:

Bertrand Coiffier

Barbara Pro

H. Miles Prince

Abstract

PURPOSE: Romidepsin is a structurally unique, potent class 1 selective histone deacetylase inhibitor. The primary objective of this international, pivotal, single-arm, phase II trial was to confirm the efficacy of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). ...

Subject

Romidepsin

Medicine

Neutropenia

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!